Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Bank of England chief economist Pill said economic activity and employment are marginally boosting demand.
2026-11-06
Bank of England chief economist Pill said economic activity and employment are marginally boosting demand.
Back
Other News
2026-11-06
Japan's real wages rose 2.2% YoY in September, the ninth consecutive monthly increase and faster than August's 1.6%, supporting the case for the Bank of Japan to continue raising rates. Average nominal wages increased 4.6% YoY to 311,409 yen, the fas
Japan's real wages rose 2.2% YoY in September, the ninth consecutive monthly increase and faster than August's 1.6%, supporting the case for the Bank of Japan to continue raising rates. Average nominal wages increased 4.6% YoY to 311,409 yen, the fastest pace since January 1997 and above August's 3.9%. Regular (base) pay rose 3.7% YoY (vs 3.8% in August). Overtime pay growth slowed to 3.6% from a revised 4.9% in August. Special payments, led by lump-sum bonuses, jumped 32.6% in September (August 1.8%); the Ministry of Health, Labour and Welfare said this spike reflects a statistical anomaly rather than higher bonus payouts. The inflation rate used to calculate the real-wage series accelerated from 2.2% in August to 2.4% in September, still below last 3.4% of the year.
2026-11-06
Moderna (MRNA.O) expects its full-year R&D expenses to be approximately $2.7 billion, up from its previous forecast of approximately $2.9 billion.
Moderna (MRNA.O) expects its full-year R&D expenses to be approximately $2.7 billion, up from its previous forecast of approximately $2.9 billion.
Chat with us
, powered by
LiveChat